Orientation Regulation of Class-switch Recombination in Human B Cells
We developed a linear amplification-mediated high-throughput genome-wide translocation sequencing method to profile Ig class-switch recombination (CSR) in human B cells in an unbiased and quantitative manner. This enables us to characterize CSR junctions resulting from either deletional recombination or inversion for each Ig class/subclass. Our data showed that more than 90% of CSR junctions detected in peripheral blood in healthy control subjects were due to deletional recombination. We further identified two major CSR junction signatures/patterns in human B cells. Signature 1 consists of recombination junctions resulting from both IgG and IgA switching, with a dominance of Sµ-Sγ junctions (72%) and deletional recombination (87%). Signature 2 is contributed mainly by Sµ-Sα junctions (96%), and these junctions were almost all due to deletional recombination (99%) and were characterized by longer microhomologies. CSR junctions identified in healthy individuals can be assigned to both signatures but with a dominance of signature 1, whereas almost all CSR junctions found in patients with defects in DNA-PKcs or Artemis, two classical nonhomologous end joining (c-NHEJ) factors, align with signature 2. Thus, signature 1 may represent c-NHEJ activity during CSR, whereas signature 2 is associated with microhomology-mediated alternative end joining in the absence of the studied c-NHEJ factors. Our findings suggest that in human B cells, the efficiency of the c-NHEJ machinery and the features of switch regions are crucial for the regulation of CSR orientation. Finally, our high-throughput method can also be applied to study the mechanism of rare types of recombination, such as switching to IgD and locus suicide switching.
Authors
- Kathrin de la Rosa (ORCID: https://orcid.org/0000-0003-4809-3157)
- Lennart Hammarström (ORCID: https://orcid.org/0000-0002-8635-9609)
- Valentyn Oksenych (ORCID: https://orcid.org/0000-0002-5088-3791)
- Hui Wan (ORCID: https://orcid.org/0000-0002-4368-8672)
- Frederick W. Alt (ORCID: https://orcid.org/0000-0002-0583-1271)
- Likun Du (ORCID: https://orcid.org/0000-0002-8448-2187)
- Mirjam van der Burg (ORCID: https://orcid.org/0000-0002-1510-3104)
- Adam Yongxin Ye (ORCID: https://orcid.org/0000-0002-1542-0740)
- Hassan Abolhassani (ORCID: https://orcid.org/0000-0002-4838-0407)
- Stelios Vlachiotis (ORCID: https://orcid.org/0000-0002-0400-1022)
- Qiang Pan‐Hammarström (ORCID: https://orcid.org/0000-0003-1990-8804)
- Xuefei Zhang (ORCID: https://orcid.org/0000-0002-1873-6679)
- Junchao Dong (ORCID: https://orcid.org/0000-0003-1182-0402)
- Xiaofei Ye (ORCID: https://orcid.org/0000-0002-7678-1152)
Institutions
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Harvard University (US)
- Sun Yat-sen University (CN)
- Max Delbrück Center (DE)
- Leiden University Medical Center (NL)
- Karolinska Institutet (SE)
- University of Bergen (NO)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.4049/jimmunol.2300842
- Citations
- 7
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Kreftforeningen
- Cancerfonden
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Norges Forskningsråd
- Center for Innovative Medicine